Recent Updates
Recently added Catalysts
CLDX

Celldex Therapeutics Announces Upcoming Presentation at the Cowen and Company 35th Annual Health Care Conference

Key Takeaway: HAMPTON, N.J., March 3, 2015 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that the Company is scheduled to present a corporate overview at the Cowen and Company 35th Annual Health Care Conference on Wednesday, March 4, at 8:40 am ET at the Boston M

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+77%
120-day peak, hindsight
Typical move
6.2%
average across 6 past catalysts
Cash runway
~37 mo
Minimal dilution risk
Lead asset
barzolvolimab
Phase 3 · Chronic Inducible Urticaria

Full Press Release Details

HAMPTON, N.J., March 3, 2015 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that the Company is scheduled to present a corporate overview at the Cowen and Company 35th Annual Health Care Conference on Wednesday, March 4, at 8:40 am ET at the Boston Marriott Copley Place Hotel in Boston, MA.
A live webcast of the presentation will be available online on the "Events & Presentations" page of the "Investors & Media" section of the Celldex website. A replay of the presentation will be available through March 11, 2015.
About Celldex Therapeutics, Inc.
Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response. Visit www.celldex.com.
Last updated: Mar 3, 2015